tiprankstipranks
Crispr Therapeutics AG (CRSP)
NASDAQ:CRSP
US Market
Want to see CRSP full AI Analyst Report?

Crispr Therapeutics AG (CRSP) Operating Expense Breakdown

11,059 Followers

Operating Expense Breakdown

Details core costs like R&D, marketing, and admin, offering insight into how efficiently the company runs and where it’s prioritizing investment.
Collaboration spend has become the dominant, highly lumpy driver of operating expense in 2024–25, suggesting milestone or partner-driven payments are replacing some in‑house work; R&D peaked in 2021–22 then stepped down, implying prioritization or outsourcing of development, while G&A remains controlled. For investors, this points to program de‑risking via partners (a positive for progress) but also to uneven cash burn and greater sensitivity of the company’s runway to the timing of collaboration milestones.
Date
Research and Development
General and Administrative
Collaboration
Mar 31, 2026
$68.57M$17.18M$45.95M
Dec 31, 2025
$83.53M$18.40M$53.70M
Sep 30, 2025
$58.90M$16.93M$57.12M
Jun 30, 2025
$69.89M$18.92M$45.15M
Mar 31, 2025
$72.48M$19.30M$57.51M
Dec 31, 2024
$82.16M$18.12M$10.42M
Sep 30, 2024
$82.16M$17.42M$11.15M
Jun 30, 2024
$80.17M$19.48M$52.13M
Mar 31, 2024
$76.17M$17.95M$46.97M
Dec 31, 2023
$95.14M$16.48M$20.00M